William Samuel David, M.D.,Ph.D.
This page shows the publications co-authored by William David and Anthony Amato.
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014 Dec 09; 83(24):2239-46.
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients =65 years old. Muscle Nerve. 2021 12; 64(6):651-656.
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019 09; 18(9):834-844.
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019 09 10; 93(11):e1093-e1103.
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8.
Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2014 Oct 14; 83(16):1453-63.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.